Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 73Neoplasm Metastasis 30Kidney Neoplasms 26Neoplasms 19Breast Neoplasms 14Prostatic Neoplasms 12Urinary Bladder Neoplasms 10Melanoma 9Gastrointestinal Stromal Tumors 9Brain Neoplasms 9Glioblastoma 8Sarcoma 7Carcinoma, Non-Small-Cell Lung 7Liver Neoplasms 6Carcinoma, Hepatocellular 6Recurrence 5Pancreatic Neoplasms 5Ovarian Neoplasms 5Esophageal Neoplasms 5Colorectal Neoplasms 5Thyroid Neoplasms 4Solid Tumors 4Osteosarcoma 4Lung Neoplasms 4Leukemia, Myeloid, Acute 4Adenocarcinoma 4Uveal Melanoma 3Thymoma 3Stomach Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

pembrolizumab 3atezolizumab 2Sugammadex 2Saline Solution 2Paclitaxel 2Neostigmine 2Gemcitabine 2Cetuximab 2zidovudine 5'-monophosphate-mannose-albumin conjugate 1tislelizumab 1testosterone 17 beta-cypionate 1temsirolimus 1relatlimab 1poly ICLC 1lenvatinib 1galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20 1delta 24-sterol reductase 1daratumumab 1cabozantinib 1abemaciclib 1Zoledronic Acid 1Water 1Valproic Acid 1Urinary Diversion 1Ultrasonography 1Trastuzumab 1Tomography, Optical Coherence 1Tissue Banks 1Therapeutics 1Testosterone Propionate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Urologic Neoplasms × Sunitinib × Clear all
NCT03541902 2026-01-09

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
32 enrolled
Genitourinary

Carcinoma, Renal Cell, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡